[Antiarrhythmic effect of sviomarin in experimental and clinical glycoside poisoning].
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy*; D004071:Digitalis Glycosides / Q000506:poisoning* / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use*; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D010042:Ouabain; D013806:Theophylline / Q000627:therapeutic use*
D004071:Digitalis Glycosides; D006634:Histamine H1 Antagonists; D010042:Ouabain; D004155:Diphenhydramine; D008012:Lidocaine; D013806:Theophylline
Antiarrhythmische Wirkung des Aviomarin bei experimenteller und klinischer Glukosidvergiftung.